Numerous clinical trials across Phase I, Phase II, and Phase III evaluate homoharringtonine protocols for acute myeloid leukemia, acute lymphoblastic leukemia, hematologic tumors, prostate cancer, and hereditary hemorrhagic telangiectasia with associated epistaxis. Supported by academic medical centers and industry sponsors, these studies encompass various recruitment statuses, including recruiting, active not recruiting, enrolling by invitation, completed, and terminated.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06855810 | RECRUITING | Acute Lymphoblastic Leukemia; Childhood Leukemia, Acute Lymphoblastic; T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma |
Institute of Hematology & Blood Diseases Hospital, China |
2025-03-11 | PHASE2; PHASE3 |
| NCT07651176 | ENROLLING_BY_INVITATION | Acute Myeloid Leukemia; Lisaftoclax |
First Affiliated Hospital of Zhejiang University |
2026-03-01 | PHASE2; PHASE3 |
| NCT07651163 | ENROLLING_BY_INVITATION | Acute Myeloid Leukemia (AML); Lisaftoclax |
First Affiliated Hospital of Zhejiang University |
2026-03-01 | PHASE2; PHASE3 |
| NCT07111598 | RECRUITING | Hereditary Haemorrhagic Telangiectasia |
Hospices Civils de Lyon |
2025-09-24 | |
| NCT06221683 | RECRUITING | AML, Childhood; Acute Myeloid Leukemia |
Children's Hospital of Soochow University |
2024-01-01 | PHASE2 |
| NCT04501120 | RECRUITING | Relapsed/Refractory Acute Myeloid Leukaemia; Myeloid Malignancy |
Ascentage Pharma Group Inc. |
2020-09-28 | PHASE1; PHASE2 |
| NCT07643636 | NOT_YET_RECRUITING | AML (Acute Myeloid Leukemia) |
Dongguan People's Hospital |
2026-06-30 | PHASE2 |
| NCT07743671 | NOT_YET_RECRUITING | Hereditary Hemorrhagic Telangiectasia |
Vaderis Therapeutics AG |
2026-09 | PHASE3 |
| NCT07131059 | RECRUITING | AML, Adult |
Institute of Hematology & Blood Diseases Hospital, China |
2024-05-11 | |
| NCT07091006 | NOT_YET_RECRUITING | Relapse Leukemia |
Ruijin Hospital |
2025-08-01 | PHASE2 |
| NCT07507825 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML) |
First People's Hospital of Hangzhou |
2026-03-31 | PHASE2 |
| NCT07469046 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML); Elderly Patients (60-75 Years) |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2026-04-10 | PHASE3 |
| NCT07505160 | NOT_YET_RECRUITING | Acute Myeloid Leukemia (AML) |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2026-03 | PHASE2 |
| NCT06265545 | RECRUITING | AML; Refractory; Relapsed |
Institute of Hematology & Blood Diseases Hospital, China |
2024-02-22 | |
| NCT06659640 | ACTIVE_NOT_RECRUITING | Hereditary Hemorrhagic Telangiectasia |
Alnylam Pharmaceuticals |
2024-11-07 | PHASE1; PHASE2 |
| NCT06328179 | RECRUITING | Acute Myeloid Leukemia |
Huai'an First People's Hospital |
2022-05-24 | |
| NCT06744556 | ACTIVE_NOT_RECRUITING | AML |
Institute of Hematology & Blood Diseases Hospital, China |
2025-01-21 | PHASE2 |
| NCT07516704 | NOT_YET_RECRUITING | Prostate Cancer |
Zhongda Hospital |
2026-04-01 | EARLY_PHASE1 |
| NCT07601425 | RECRUITING | Hereditary Hemorrhagic Telangiectasia (HHT); Osler Weber Rendu Disease |
Atavistik Bio, Inc |
2026-07-27 | PHASE1; PHASE2 |
| NCT07163910 | RECRUITING | Prostate Cancer |
baotai Liang |
2025-04-20 | PHASE2 |
| NCT07159906 | NOT_YET_RECRUITING | Diffuse Large B-Cell Lymphoma; Relapsed Non-Hodgkin Lymphoma; Refractory Non-Hodgkin Lymphoma |
First Affiliated Hospital of Zhejiang University |
2025-09-08 | PHASE1; PHASE2 |
| NCT05406362 | ACTIVE_NOT_RECRUITING | Hereditary Hemorrhagic Telangiectasia (HHT) |
Vaderis Therapeutics AG |
2022-07-18 | PHASE1; PHASE2 |
| NCT07517510 | ENROLLING_BY_INVITATION | Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL) |
Guangdong Second Provincial General Hospital |
2026-04-01 | PHASE2 |
| NCT04976036 | RECRUITING | Telangiectasia, Hereditary Hemorrhagic |
Dr. Romain Lazor |
2022-05-05 | PHASE2 |
| NCT06834321 | RECRUITING | Prostate CA |
baotai Liang |
2025-03-19 | PHASE2 |
| NCT06483906 | RECRUITING | Acute Myeloid Leukemia |
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine |
2024-07-02 | PHASE2 |
| NCT06742463 | RECRUITING | Acute T Lymphpblastic Leukemia/Lymphoma |
First Affiliated Hospital of Zhejiang University |
2024-12 | PHASE2 |
| NCT06810791 | RECRUITING | Newly Diagnosed Acute Myeloid Leukemia With High Risk |
Nanfang Hospital, Southern Medical University |
2025-01-01 | PHASE3 |
| NCT06361329 | RECRUITING | ETP-ALL |
First Affiliated Hospital of Zhejiang University |
2024-04-03 | PHASE3 |
| NCT04404881 | ACTIVE_NOT_RECRUITING | Hereditary Hemorrhagic Telangiectasia |
Hanny Al-Samkari, MD |
2020-11-23 | PHASE2 |
| NCT03850730 | UNKNOWN | Hereditary Hemorrhagic Telangiectasia; Epistaxis |
Cure HHT |
2023-07-01 | PHASE1; PHASE2 |
| NCT05906914 | COMPLETED | Acute Myeloid Leukemia, Adult |
First Affiliated Hospital of Zhejiang University |
2022-10-26 | PHASE2 |
| NCT05805098 | RECRUITING | Acute Myeloid Leukemia |
The First Affiliated Hospital of Soochow University |
2023-03-01 | PHASE2; PHASE3 |
| NCT05941585 | COMPLETED | Acute Myeloid Leukemia |
Institute of Hematology & Blood Diseases Hospital, China |
2023-08-08 | |
| NCT05726110 | RECRUITING | Relapsed or Refractory Acute Myeloid Leukemia |
Shanxi Bethune Hospital |
2023-01-29 | PHASE3 |
| NCT05269849 | COMPLETED | Hereditary Hemorrhagic Telangiectasia; Nosebleeds; Epistaxis |
Unity Health Toronto |
2022-03-16 | PHASE2 |
| NCT04126681 | COMPLETED | Chronic Myeloid Leukemia, Chronic Phase |
Ascentage Pharma Group Inc. |
2019-10-21 | PHASE2 |
| NCT05805072 | UNKNOWN | Relapsed/Refractory AML |
The First Affiliated Hospital of Soochow University |
2023-05-01 | |
| NCT04824924 | UNKNOWN | Leukemia, Myeloid, Acute |
Shanghai Jiao Tong University School of Medicine |
2021-03 | PHASE2 |
| NCT04646356 | COMPLETED | Hereditary Hemorrhagic Telangiectasia; Epistaxis Nosebleed |
Unity Health Toronto |
2020-10-20 | PHASE2 |
| NCT06259292 | Recruiting | Hereditary Hemorrhagic Telangiectasia|Arteriovenous Malformations|Telangiectasia|Epistaxis|GastroIntestinal Bleeding|Cerebral Arteriovenous Malformations|Vascular Malformation |
Cure HHT|Augusta University|The Cleveland Clinic|Mayo Clinic|Massachusetts General Hospital|Columbia University|Oregon Health and Science University|University of California Los Angeles|University of California San Francisco|University of Colorado Denver|University of North Carolina Chapel Hill|University of Pennsylvania|University of Texas|University of Utah|Washington University School of Medicine|Yale University|Health Resources and Services Administration (HRSA)|Children''s Hospital of Philadelphia |
2023-11-13 | -- |
| NCT05513131 | UNKNOWN | Secondary Acute Myeloid Leukemia |
The First Affiliated Hospital with Nanjing Medical University |
2021-09-30 | PHASE2 |
| NCT05954481 | Recruiting | Hereditary Hemorrhagic Telangiectasia|Rendu Osler Disease |
Hospices Civils de Lyon |
2023-08-03 | Not Applicable |
| NCT06266624 | ACTIVE_NOT_RECRUITING | HHT |
University Hospital, Essen |
2020-09-25 | |
| NCT03850964 | Recruiting | Hereditary Hemorrhagic Telangiectasia|Epistaxis|Anemia|Nosebleed|HHT |
Cure HHT |
2023-05-08 | Phase 2|Phase 3 |
| NCT03954782 | COMPLETED | Telangiectasia, Hereditary Hemorrhagic; Rendu Osler Disease |
Hospices Civils de Lyon |
2020-06-22 | PHASE2 |
| NCT04505995 | UNKNOWN | JMML |
Air Force Military Medical University, China |
2020-01-01 | |
| NCT05457361 | UNKNOWN | Venetoclax Combined With Azacitidine Plus Homoharringtonine; Venetoclax Combined With Azacitidine |
Nanfang Hospital, Southern Medical University |
2022-03-01 | PHASE3 |
| NCT04248595 | UNKNOWN | Acute Myeloid Leukemia |
Ge Zheng |
2019-12-01 | PHASE2 |
| NCT03978364 | UNKNOWN | Myelodysplastic Syndromes,Acute Myeloid Leukemia |
Shandong Provincial Hospital |
2019-06-01 | PHASE3 |
| NCT04976036 | Recruiting | Telangiectasia Hereditary Hemorrhagic |
Dr. Romain Lazor|Boehringer Ingelheim|Centre Hospitalier Universitaire Vaudois |
2022-05-05 | Phase 2 |
| NCT04083911 | UNKNOWN | Acute Myeloid Leukemia; Induction Chemotherapy |
The First Affiliated Hospital of Soochow University |
2019-04-01 | PHASE3 |
| NCT04108052 | COMPLETED | Telangiectasia, Hereditary Hemorrhagic; Rendu Osler Disease |
Hospices Civils de Lyon |
2019-11-28 | |
| NCT06266624 | Active not recruiting | HHT |
University Hospital Essen |
2020-09-25 | Not Applicable |
| NCT03227263 | COMPLETED | Rendu Osler Disease; Telangiectasia, Hereditary Hemorrhagic |
Hospices Civils de Lyon |
2017-09-28 | PHASE3 |
| NCT02389959 | COMPLETED | HHT; Hereditary Hemorrhagic Telangiectasia; Epistaxis; Nose Bleeds; Nasal Bleeding |
Stanford University |
2014-08-04 | PHASE4 |
| NCT03453255 | UNKNOWN | Chemotherapy |
Chinese PLA General Hospital |
2018-01-01 | PHASE1; PHASE2 |
| NCT03910244 | Completed | Telangiectasia Hereditary Hemorrhagic |
The Cleveland Clinic|RTI International |
2019-10-17 | Phase 2 |
| NCT02638012 | COMPLETED | Hereditary Hemorrhagic Telangiectasia (HHT); Epistaxis |
Unity Health Toronto |
2015-12 | |
| NCT01752049 | COMPLETED | Hereditary Hemorrhagic Telangiectasia |
Unity Health Toronto |
2013-05 | PHASE1; PHASE2 |
| NCT03152019 | COMPLETED | Hemorrhagic Hereditary Telangiectasia (HHT) |
Hospices Civils de Lyon |
2017-05-22 | PHASE2 |
| NCT02484716 | COMPLETED | Telangiectasia, Hereditary Hemorrhagic; Osler Rendu Disease |
Hospices Civils de Lyon |
2015-06 | PHASE2 |
| NCT02106520 | TERMINATED | Hereditary Hemorrhagic Telangiectasia; Epistaxis |
Hospices Civils de Lyon |
2014-04 | PHASE2; PHASE3 |
| NCT02464644 | COMPLETED | Hereditary Hemorrhagic Telangiectasia (HHT) |
Imperial College London |
2012-04 | |
| NCT01485224 | COMPLETED | Hereditary Hemorrhagic Telangiectasia; Epistaxis |
Fondazione IRCCS Policlinico San Matteo di Pavia |
2011-11 | PHASE2 |
| NCT01408030 | COMPLETED | Telangiectasia, Hereditary Hemorrhagic; Epistaxis |
James Gossage |
2011-08 | PHASE2 |
| NCT01397695 | COMPLETED | Hereditary Hemorrhagic Telangiectasia (HHT) |
University of California, San Diego |
2009-06 | PHASE2 |
| NCT01402531 | COMPLETED | Hereditary Hemorrhagic Telangiectasia (HHT) |
University of California, San Diego |
2010-07-22 | PHASE2 |
| NCT01406639 | WITHDRAWN | Hereditary Hemorrhagic Telangiectasia (HHT); Nosebleeds |
University of California, San Diego |
2011-07 | PHASE1 |
| NCT00375219 | COMPLETED | Chronic Myeloid Leukemia |
Teva Branded Pharmaceutical Products R&D, Inc. |
2006-09-20 | PHASE2 |
| NCT00462943 | COMPLETED | Chronic Myeloid Leukemia |
Teva Branded Pharmaceutical Products R&D, Inc. |
2007-03-07 | PHASE2 |
| NCT00843440 | COMPLETED | Hemorrhagic Hereditary Telangiectasia |
Hospices Civils de Lyon |
2009-03 | PHASE2 |
| NCT00675350 | COMPLETED | Hematologic Tumors |
ChemGenex Pharmaceuticals |
2008-04 | PHASE1 |
| NCT00114959 | TERMINATED | Myeloid Leukemia, Chronic; Myeloid Leukemia, Chronic, Accelerated-Phase; Blast Phase; Myeloid Leukemia, Chronic, Chronic-Phase |
ChemGenex Pharmaceuticals |
2005-10 | PHASE2 |
| NCT00006364 | COMPLETED | Childhood Chronic Myelogenous Leukemia; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase Chronic Myelogenous Leukemia; Relapsing Chronic Myelogenous Leukemia |
National Cancer Institute (NCI) |
1999-11 | PHASE2 |
| NCT00003694 | COMPLETED | Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Chronic Phase Chronic Myelogenous Leukemia |
National Cancer Institute (NCI) |
1999-03 | PHASE2 |
| NCT00003239 | COMPLETED | Leukemia |
M.D. Anderson Cancer Center |
1998-03 | PHASE2 |
| NCT00002574 | COMPLETED | Leukemia |
National Cancer Institute (NCI) |
1994-09 | PHASE2 |
| NCT00004933 | TERMINATED | Leukemia |
Alliance for Clinical Trials in Oncology |
2000-01 | PHASE3 |
| NCT00030355 | WITHDRAWN | Leukemia |
National Cancer Institute (NCI) |
PHASE1; PHASE2 |
(data from https://clinicaltrials.gov, updated on 2025-08-26)
Check the
Homoharringtonine (HHT)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- Homoharringtonine (HHT) Solubility in DMSO
- Homoharringtonine (HHT) Stock Solution
- Homoharringtonine (HHT) Storage
- Homoharringtonine (HHT) Stability
- Homoharringtonine (HHT) Molecular Weight
- Homoharringtonine (HHT) SMILES
- Homoharringtonine (HHT) CAS Number
- Homoharringtonine (HHT) Chemical Structure (2D and 3D)
- Homoharringtonine (HHT) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.